arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

ARROWHEAD PHARMACEUTICALS, INC.

ARWR
$57.45 ▼ -4.23 (-6.86%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
23 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
56
Health
Fair
Neutral
auto_awesome

Analytical Summary

ARROWHEAD PHARMACEUTICALS, INC. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $7.7B
Dividend Yield —
Revenue Growth 23258.2% ↗
Op. Margin 11.9%
ROIC 12.3% ↗
FCF / Share $1.17 ↗
Trailing P/E —
Price / Book 16.7x
FCF Yield 2.0%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

23-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$829.45M
↑ +23258.2% —
Net Income Profit after all expenses
$-1.63M
↑ +99.7% —
Operating Margin Operating profit as % of sales
11.9%
↑ +113.9% 61th
FCF / Share Free cash flow per share
$1.17
↑ +123.2% —

Health Breakdown

Profitability ↑
57
Returns ↑
43
Financial Health
100
Cash Quality ↓
0

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 23 years · 84 quarters